Because the tumor genetic profile may impact survival, we analyzed the Pathology Atlas data and found that (i) higher expression of IFI30, GBP1 and GBP4 was associated with better 5-year survival rate in breast cancer as well as in skin cutaneous melanoma, (ii) higher expression of GBP1 and GBP4 was associated with better 5-year survival rate in colorectal and stomach cancer, and (iii) higher expression of IFI30 was associated with worse 5-year survival rate in colorectal and stomach cancer (Table S14). Here, GBP4 is linked to breast carcinoma.